Paratek Pharmaceuticals Inc
Paratek Pharmaceuticals is dedicated to addressing antimicrobial resistance (AMR) and developing innovative treatment options for complex medical issues. The company is committed to ethical business practices, scientific research, and providing educational resources for healthcare professionals. Their flagship product NUZYRA® is an FDA-approved antibiotic targeting adult patients with CABP and ABSSSI caused by susceptible bacteria. Paratek also actively engages in medical education, clinical research, and collaboration with healthcare professionals to improve patient care and combat global health threats.
Industries
Nr. of Employees
large (251-1000)
Paratek Pharmaceuticals Inc
King of Prussia, 1000 First Avenue, Suite 200, King of Prussia, PA 19406
Patents
9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
US-10835542-B2
View Details9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
US-10383884-B2
View Details
9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
US-10835542-B2
View Details9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
US-10383884-B2
View DetailsProducts
FDA‑approved tetracycline‑class antibiotic (omadacycline)
A tetracycline‑class antibiotic approved for use in adults for community‑acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible organisms.
FDA‑approved tetracycline‑class antibiotic (omadacycline)
A tetracycline‑class antibiotic approved for use in adults for community‑acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible organisms.
Services
Telephone and email medical information service for healthcare professionals, with intake, triage and follow‑up by medical science staff.
Evaluation and funding of investigator‑initiated research proposals and educational grants to support clinical and preclinical research and independent medical education.
Channels for reporting adverse events and product quality complaints via phone, web form or dedicated submission portals, with procedures for case handling and regulatory reporting.
Information and coordination for submission of isolates and susceptibility testing via external reference laboratories, including guidance on phenotypic methods and testing workflows.
Online access to centralized pathogen susceptibility surveillance datasets for comparative activity and trend analysis.
Requestable follow‑up consultation with a medical science director to discuss product information, research ideas or scientific data.
Telephone and email medical information service for healthcare professionals, with intake, triage and follow‑up by medical science staff.
Evaluation and funding of investigator‑initiated research proposals and educational grants to support clinical and preclinical research and independent medical education.
Channels for reporting adverse events and product quality complaints via phone, web form or dedicated submission portals, with procedures for case handling and regulatory reporting.
Information and coordination for submission of isolates and susceptibility testing via external reference laboratories, including guidance on phenotypic methods and testing workflows.
Online access to centralized pathogen susceptibility surveillance datasets for comparative activity and trend analysis.
Requestable follow‑up consultation with a medical science director to discuss product information, research ideas or scientific data.
Expertise Areas
- Antimicrobial resistance research
- Antibiotic drug development
- Clinical trial management for anti‑infectives
- Preclinical infectious disease modeling
Key Technologies
- Phenotypic susceptibility testing (broth microdilution, agar dilution, disk diffusion)
- MIC gradient strip testing
- Metagenomic sequencing and analysis
- PK‑PD modeling and simulation
News & Updates
Latest press releases and news updates about Paratek Pharmaceuticals.
Creating an expanded portfolio of specialty therapies.
Details about upcoming clinical data presentations.
FDA Approval of NUZYRA®
NUZYRA® received FDA approval for the treatment of certain bacterial infections.
Acquisition of Optinose
Paratek completed the acquisition of Optinose to expand its portfolio.
Latest press releases and news updates about Paratek Pharmaceuticals.
Creating an expanded portfolio of specialty therapies.
Details about upcoming clinical data presentations.
FDA Approval of NUZYRA®
NUZYRA® received FDA approval for the treatment of certain bacterial infections.
Acquisition of Optinose
Paratek completed the acquisition of Optinose to expand its portfolio.